Sarepta share price drops again after third gene therapy death
Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment. A …
Post
-
-
Velocity and Palantir to automate trial payment reconciliation processes
Velocity Clinical Research has partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials, marking an advancement …
-
UroMems awarded FDA IDE to use artificial urinary sphincter in pivotal trial
UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI). The company was …
-
Novartis culls ianalumab in HS after Phase IIb trial failure
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet …
-
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder
The UK Medical and Healthcare products Regulatory Agency (MHRA) has granted approval for Cybin to initiate the randomised EMBRACE study …
-
The rise of prediabetes in US teens increases adulthood morbidity
According to the US Centers for Disease Control and Prevention (CDC), a third of US teenagers are prediabetic, meaning that …
-
World Brain Day: brain health and an ageing population
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and …
-
Accurate data interpretation key to expanding RWE in trials
While more companies are using real-world data (RWD) and real-world evidence (RWE) in research, there are still barriers that continue …
-
Aptar acquires Mod3 Pharma’s trial materials manufacturing capabilities
Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings. Mod3 Pharma was previously …
-
AstraZeneca’s AL amyloidosis drug fails to impress in Phase III
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A …
-
OKYO reports top-line data from neuropathic corneal pain therapy trial
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod (previously referred to as OK-101), …
-
Chronic conditions increase in US children over last decade
This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia …
-
UK Government targets manufacturing as it eyes £41bn life science sector growth
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
-
PEPFAR funding protection offers “hope” for people living with HIV
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
-
SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML
SELLAS Life Sciences’ CDK9 inhibitor, SLS009, for relapsed/refractory acute myeloid leukaemia (r/r AML) is set to advance after it met …
